Application of mitochondrial extract for treating or / and preventing kidney injury related diseases
Patent Information
- Application Number
- JP2024112807
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-03-20
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2041-03-19
AI Technical Summary
Current treatments for chronic kidney disease and renal fibrosis are inadequate, lacking effective methods to address the underlying mechanisms and progression of kidney damage, leading to severe health burdens and high medical costs.
Utilizing mitochondrial extracts derived from various stem cell types to prepare compositions that can be administered to improve or prevent kidney damage-related diseases, including renal fibrosis, inflammation, and other kidney disorders.
The mitochondrial extracts effectively improve mitochondrial damage in renal cells, reducing collagen secretion, preventing cell death, and ameliorating kidney diseases by enhancing cell viability and reducing fibrosis, as demonstrated through in vitro and in vivo models.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to secondary uses of the mitochondrial extract, in particular to the use of the mitochondrial extract for treating and / or preventing diseases associated with kidney damage. [Background technology]
[0002] Mitochondria are one of the organelles present in human cells, and they supply ATP necessary for normal cell activity. Recent studies have shown that an increase in the number and activation of mitochondria in cells supplies the energy necessary for stem cell differentiation, contributing to successful stem cell differentiation. In other words, mitochondria play a very important role in the energy metabolism of the human body. For example, if there is a defect in mitochondria, degenerative or age-related diseases such as Alzheimer's, myasthenia gravis, and muscle diseases will occur. Currently, many studies have pointed out that if patients with Parkinson's disease or Alzheimer's disease caused by oxidative damage can maintain normal mitochondrial function and increase the antioxidant capacity in the body, it will contribute to suppressing the deterioration of neurodegenerative diseases.
[0003] A condition in which damage to renal tissue continues for more than three months and the structure and function of the kidney cannot be restored to its original state is called chronic kidney disease. Currently, in clinical practice, drug therapy is the main treatment, and many treatments are supplemented by diet and lifestyle control. However, as chronic kidney disease worsens over time and kidney function is gradually lost due to renal fibrosis, patients will need to undergo hemodialysis or kidney transplants to maintain their lives. This is a very painful process for patients and also a high burden on national medical expenses. In other words, because knowledge about the pathogenesis and treatment methods of chronic kidney disease is still unclear, it is the current situation that effective treatment methods for chronic kidney disease cannot be provided in clinical practice. Therefore, it is urgent in clinical medicine to provide compositions and methods effective for treating chronic kidney disease and renal fibrosis. Summary of the Invention [Problem to be solved by the invention]
[0004] The main objective of the present invention is to provide a secondary use of a mitochondrial extract, which can effectively improve or prevent renal impairment-related diseases, thereby achieving the effects of treating kidney disease and inhibiting the aggravation of kidney disease. [Means for solving the problem]
[0005] In order to achieve the above-mentioned object, the present invention discloses the use of a mitochondrial extract in preparing a composition for preventing and / or treating a renal dysfunction-related disease. Specifically, when a certain amount of a mitochondrial extract is administered to an individual suffering from a renal dysfunction-related disease, it can improve renal cell damage, thereby achieving the effect of treating or preventing the worsening of a renal dysfunction-related disease.
[0006] In the embodiments of the present invention, the renal damage-related diseases include renal fibrosis, renal inflammation, chronic kidney disease, acute kidney injury, tubular injury, renal failure, prerenal kidney injury, nephrogenic kidney injury, postrenal kidney injury, glomerulonephritis, pyelonephritis, nephrotic syndrome, and uremia.
[0007] In one embodiment of the present invention, the kidney damage-related disease has, in addition to mitochondrial damage, at least one of the following symptoms: proteinuria, edema, oliguria, high urea nitrogen, high creatinine, abnormal uric acid levels, stones, and abnormal glomerular filtration rate.
[0008] In another embodiment of the present invention, mitochondria are isolated from stem cells, such as adipose stem cells, CD34+ hematopoietic stem cells, mesenchymal stem cells, bone marrow stem cells, umbilical cord stem cells, amniotic stem cells, amniotic fluid stem cells, placental stem cells, iPS cells, neural stem cells, etc.
[0009] In the embodiment of the present invention, the amount of mitochondria in the composition is 5-80 μg, preferably the amount of mitochondria in the composition is 40 μg. Effect of the Invention
[0010] The beneficial effects of the present invention are as follows: When mitochondrial damage occurs in renal cells due to the environment, such as fibrosis, oxidative stress, or inflammation, the mitochondrial damage in renal cells can be effectively improved by administering the mitochondrial extract provided by the present invention or a composition containing the same, thereby achieving the effect of improving or treating renal cell damage and related diseases. [Brief description of the drawings]
[0011] [Figure 1A] This is the result of a statistical analysis of the survival rate of renal epithelial cells 24 hours after treatment with different concentrations of hydrogen peroxide. [Figure 1B] This is a statistical analysis of the survival rate of renal epithelial cells after treatment with different concentrations of hydrogen peroxide and subsequent administration of different doses of mitochondrial precipitates. [Figure 2A] This shows the results of detecting and analyzing the amount of collagen secreted by renal epithelial cells after treating them with different concentrations of advanced glycation end products (AGEs-BSA) for different periods of time. [Figure 2B] Renal epithelial cells were treated with different concentrations of AGEs-BSA and administered different doses of mitochondrial precipitates, and then the amount of collagen secreted by the renal epithelial cells was detected and analyzed. [Figure 2C] The figures show the results of detecting and analyzing the amount of collagen secreted by renal epithelial cells after treating them with different concentrations of hydrogen peroxide and administering different doses of mitochondrial precipitates. [Diagram 3] The results show that renal epithelial cells were treated with hydrogen peroxide or AGEs-BSA, and different doses of mitochondrial precipitates were administered, and then the state of mitochondrial damage in the renal epithelial cells was detected and analyzed. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The present invention provides a secondary use of the mitochondrial extract, namely, that by administering a certain amount of the mitochondrial extract or a composition containing the same to an individual suffering from a renal damage-related disease, the renal damage-related disease can be effectively improved and the worsening of the renal damage-related disease can be prevented.
[0013] Usually, the dose of mitochondria provided by the present invention administered to an individual is 5 to 80 μg, for example, 5, 10, 15, 20, 25, 30, 40, 50, 60, 65, 70, 80 μg, etc., and among these, the administration dose is preferably 15 to 40 μg. Furthermore, in order to achieve an excellent effect of treating or improving kidney disease, the mitochondria provided by the present invention may be combined with other components to prepare a composition, and the components to be combined preferably have growth factors, such as blood products containing growth factors, platelet-rich plasma (PRP), plasma, serum, platelet-rich fibrin, etc.
[0014] In the present invention, the term "mitochondrial extract" refers to mitochondria isolated from cells, and the isolation technique or method used must be capable of maintaining the integrity of mitochondrial structure and function. To those skilled in the art of the present invention, the isolation technique or method may be physical or chemical.
[0015] In the present invention, the term "cell" refers to cells having mitochondria, such as adipose stem cells, mesenchymal stem cells, skeletal muscle cells, liver cells, kidney cells, fibroblasts, nerve cells, skin cells, and blood cells.
[0016] In the present invention, the "composition" may be a pharmaceutical composition, a food, a functional food, a nutritional supplement, etc., and may be a combination of various ingredients according to the type, and may have various dosage forms and various administration methods.
[0017] In the present invention, a "nephropathy-related disease" refers to a disease caused by damage to renal cells, and has symptoms of mitochondrial damage, such as renal fibrosis, renal inflammation, kidney disease, acute kidney injury, tubular injury, renal failure, prerenal kidney injury, nephrogenic kidney injury, postrenal kidney injury, glomerulonephritis, pyelonephritis, nephrotic syndrome, and uremia.
[0018] In the following, in order to demonstrate the effects of the mitochondrial extract provided by the present invention, a detailed description will be given with reference to several examples and drawings.
[0019] Although the mitochondria used in the following examples are derived from human adipose-derived stem cells, the mitochondria of the present invention are not limited to those derived from human adipose stem cells, i.e., the mitochondria of the present invention may be derived from any cell of the human body.
[0020] The doses of mitochondria used in the following examples are merely examples, and although a dose of 15 μg of mitochondria represents a low dose and a dose of 40 μg represents a high dose, they in no way limit the technical features of the present invention. That is, the mitochondria provided by the present invention can achieve the effects that the present invention aims to achieve at any dose of 5 to 80 μg. EXAMPLES
[0021] Culture of renal epithelial cell lines
[0022] Renal epithelial cell lines were cultured in a cell culture medium containing MEM-α Earl's salt and 5% fetal bovine serum, and cultured at 37°C (containing 5% carbon dioxide). When the cell culture reached 80% confluence, the cell culture medium was removed, the cells were washed with phosphate buffer, and after removing the phosphate buffer, 0.25% trypsin / 2.21 mM EDTA was added and reacted for 20 minutes, and then MEM-α containing 5% fetal bovine serum was added to neutralize the trypsin. The suspended cells were collected and centrifuged, after which the cells were counted, and the cells were further resuspended in MEM-α containing 5% fetal bovine serum until the final concentration reached 5x10 4The cells / mL were diluted for subsequent subculture or analysis. EXAMPLES
[0023] Extraction of mitochondria
[0024] Human adipose stem cells were cultured at 1.5x10 cells. 8 The cells were cultured until they were cells, washed with Dulbecco's phosphate buffer (DPBS), then the Dulbecco's phosphate buffer was removed, trypsin was added and reacted for 3 minutes, then stem cell culture medium (Keratinocyte SFM (1X) liquid, bovine pituitary extract, 10wt% fetal bovine serum) was added to terminate the reaction, the cells were collected and centrifuged (600g, 10 minutes), the supernatant was removed, 80mL of IBC-1 buffer (buffer (225mM mannitol, 75mM sucrose, 0.1mM EDTA, 30mM Tris-HCl pH 7.4)) was added to the cells, homogenized, and centrifuged, and the resulting precipitated material was mitochondria (hereinafter referred to as mitochondrial precipitate). 1.5mL of IBC-1 buffer and protease inhibitor were added to the mitochondrial precipitate, placed at 4°C, and used in the following examples. EXAMPLES
[0025] Renal epithelial cell injury test (1)
[0026] The renal epithelial cells cultured in Example 1 were subcultured in a 96-well plate at a concentration of 5x10 per well. 4After culturing for 8 hours, the supernatant was removed and washed with phosphate buffer, and then 200 μL of cell culture medium without 5% fetal bovine serum was added to each well and cultured for 8 hours. After culturing, the cells were treated with different concentrations of hydrogen peroxide (0.3, 0.5, 1, 3, 5, 10 mM). After culturing for 24 hours with different concentrations of hydrogen peroxide, the supernatant of each well was removed and cell culture medium containing 10% Alamar blue was added (100 μL / well), and the cells were cultured for 3 to 4 hours, after which fluorescence fingerprint measurement (Excitation / Emission: 560 / 590 nm) was performed. The results are shown in Figure 1A.
[0027] From the results in FIG. 1A, it can be seen that after renal epithelial cells were cultured with different concentrations of hydrogen peroxide for 24 hours, renal epithelial cells began to be damaged. Among them, when the concentration of hydrogen peroxide was 1 mM or more, the situation in which renal epithelial cells were damaged and died increased significantly. Specifically, the survival rate of renal epithelial cells after treating renal epithelial cells with hydrogen peroxide at a concentration of 1 mM for 24 hours was 81.4%, the survival rate of renal epithelial cells after treating renal epithelial cells with hydrogen peroxide at a concentration of 5 mM for 24 hours was 31.3%, and the survival rate of renal epithelial cells after treating renal epithelial cells with hydrogen peroxide at a concentration of 10 mM for 24 hours was 24.2%. This result shows that a renal epithelial cell injury and death model can be constructed by treating renal epithelial cells with hydrogen peroxide, and that as the concentration of hydrogen peroxide added increases, the injury state of renal epithelial cells worsens and the number of renal epithelial cells who die also increases. EXAMPLES
[0028] Renal epithelial cell injury test (2)
[0029] The renal epithelial cells cultured in Example 1 were subcultured in a 96-well plate at a concentration of 1x10 per well. 4After culturing for 8 hours, the supernatant was removed, washed with phosphate buffer, and 200 μL of cell culture solution not containing 5% fetal bovine serum was added to each well and cultured for 8 hours. Then, the cells were treated with hydrogen peroxide at concentrations of 1 mM and 3 mM for 4 hours, and different doses (15 μg and 40 μg) of mitochondrial precipitate (prepared in Example 2) were given to the cells treated with hydrogen peroxide at different concentrations, and then cultured for 24 hours. After the culture was completed, the supernatant was removed, and a cell culture solution containing 10% Alamar Blue was added (100 μL / well), and cultured for 3 to 4 hours in an environment of 37 ° C., and then a fluorescent fingerprint measurement (Excitation / Emission: 560 / 590 nm) was performed at the end of the culture. The results are shown in Figure 1B.
[0030] The results in Figure 1B show that renal epithelial cells treated with hydrogen peroxide are damaged and have a reduced cell viability, but administration of a certain amount of mitochondrial precipitate to renal epithelial cells damaged by hydrogen peroxide can significantly improve the viability of the renal epithelial cells, and the viability of the renal epithelial cells increases with increasing dose.
[0031] These results demonstrate that the mitochondrial extract provided by the present invention can indeed protect renal epithelial cells, prevent the occurrence of damage to renal epithelial cells caused by oxidation or inflammatory reactions, and can repair damaged renal epithelial cells and effectively prevent the death of renal epithelial cells. In other words, the mitochondrial extract provided by the present invention or a composition containing the same certainly has the effect of improving and / or preventing kidney damage or kidney disease caused by oxidative stress. EXAMPLES
[0032] Renal epithelial cell fibrosis test (1)
[0033] The renal epithelial cells cultured in Example 1 were cultured in a 6-well plate in a culture medium containing 5% fetal bovine serum at a concentration of 1 x 10 5After culturing for 24 hours, the supernatant was removed and washed with phosphate buffer, 1 ml of cell culture medium not containing 5% fetal bovine serum was added to each well and cultured for 8 hours, and then advanced glycation end products (AGEs-BSA) of different concentrations (100 μg / ml and 400 μg / ml) were added and cultured for 4 hours. After the culture was completed, the cell culture medium containing AGEs-BSA was removed and washed with phosphate buffer, and 1 ml of cell culture medium not containing 5% fetal bovine serum was added to each well and cultured for 24 and 48 hours, respectively. After the culture was completed, the supernatant was collected and collagen secretion was measured using a soluble collagen measurement kit (Sircol (registered trademark) Soluble Collagen Assay Kit). The results are shown in Figure 2A.
[0034] The results in Figure 2A show that the expression level of collagen secretion in renal epithelial cells increased in both renal epithelial cells treated with high concentration (400 μg / ml) and low concentration (100 μg / ml) AGEs-BSA, and that the expression level of collagen secretion increased as the treatment time increased, indicating that AGEs-BSA certainly induces lesions in renal epithelial cells and produces a fibrotic state. This is the early stage of chronic kidney disease, and if the expression level of collagen secretion continues to increase, chronic kidney disease will develop. EXAMPLES
[0035] Renal epithelial cell fibrosis test (2)
[0036] The process of this example was almost the same as that of Example 5, except that the cell culture medium containing AGEs-BSA was removed, and then cell culture medium not containing 5% fetal bovine serum and different doses (15 μg and 40 μg) of mitochondrial precipitate (prepared in Example 2) were added to each well, and then each was cultured for 24 hours. After the culture was completed, the supernatant was collected and collagen secretion was measured using a water-soluble collagen measurement kit. The results are shown in Figure 2B.
[0037] The results in FIG. 2B demonstrate that administration of mitochondrial precipitates can reduce the amount of collagen secretion in renal epithelial cells induced by AGEs-BSA, demonstrating that the mitochondria or a composition containing the mitochondria provided by the present invention can effectively improve and / or prevent renal fibrosis and associated kidney diseases. EXAMPLES
[0038] Renal epithelial cell fibrosis test (3)
[0039] The steps of this example were generally the same as those of Example 6, except that the stimulant for inducing fibrosis in renal epithelial cells was changed from AGEs-BSA to hydrogen peroxide. The measurement results are shown in Figure 2C.
[0040] From the results in FIG. 2C, it can be seen that treatment of renal epithelial cells with hydrogen peroxide induces an increase in collagen secretion. In other words, it is possible to construct a renal cell fibrosis model by treating renal epithelial cells with hydrogen peroxide. When mitochondrial precipitates were given to renal epithelial cells that had been treated with hydrogen peroxide, the amount of collagen secreted from the renal epithelial cells could be significantly reduced, demonstrating that the mitochondria or a composition containing the mitochondria provided by the present invention can effectively improve and / or prevent renal fibrosis and associated kidney diseases. EXAMPLES
[0041] Testing for impairment of mitochondrial function in renal epithelial cells
[0042] The renal epithelial cells cultured in Example 1 were subcultured in a 96-well plate in a cell culture medium containing 5% fetal bovine serum at a concentration of 5x10 per well. 4The cells were cultured for 24 hours, the supernatant was removed, washed with phosphate buffer, 1 ml of cell culture solution not containing 5% fetal bovine serum was added to each well and cultured for 8 hours, then cultured for 4 hours with 3 mM hydrogen peroxide and 100 μg / ml AGEs-BSA, respectively, after which the cell culture solution containing hydrogen peroxide or AGEs-BSA was removed, washed with phosphate buffer, 1 ml of cell culture solution not containing 5% fetal bovine serum and different doses (15 μg and 40 μg) of mitochondrial precipitate (prepared in Example 2) were added to each well and cultured for 24 hours, respectively, washed with phosphate buffer after culture completion, added a buffer containing 10 μM JC-1 staining reagent, reacted at 37 ° C for 10 minutes, washed, and then performed fluorescence fingerprint measurement (Excitation / Emission: 488 / 530 nm). The results are shown in Figure 3.
[0043] The results in Figure 3 show that renal epithelial cells treated only with hydrogen peroxide or AGEs-BSA showed increased expression of JC-1 monomer. This indicates that mitochondria in renal epithelial cells were damaged by the inflammatory environment created by hydrogen peroxide or AGEs-BSA. On the other hand, renal epithelial cells treated with different doses of mitochondrial precipitates after first being treated with hydrogen peroxide or AGEs-BSA showed a significant decrease in the expression of JC-1 monomer, and as the dose of mitochondrial precipitates increased, the expression of JC-1 monomer in renal epithelial cells also decreased. EXAMPLES
[0044] Animal testing
[0045] Ten-week-old C57BL / 6 mice were prepared and bred in a constant temperature and humidity environment with a 12:12-hour light-dark cycle. The mouse kidney injury model was an ischemia-reperfusion model (hereinafter referred to as the I / R kidney injury model). The procedure is as follows. First, 150 mg / kg of phenobarbital was injected intraperitoneally into the abdomen of the mouse to put the mouse into a coma, and then surgery was performed at the left kidney position of the mouse. The left kidney was exposed from the incision, and the renal artery blood vessels flowing to the kidney were blocked with a vascular clamp, and after blocking for 30 minutes, the vascular clamp was removed and blood flow was allowed to resume, completing the I / R kidney injury model.
[0046] Mice that underwent I / R kidney injury model treatment were injected with different doses of mitochondria (15μg and 40μg) into the kidneys via renal artery vascular injection to create high and low mitochondria dose groups. The control group (I / R group) was injected with phosphate buffer. After the treatments were completed for each group of mice, the kidneys were returned to the body and the wounds were sutured. Blood samples were collected on the first (D1) and second (D2) days after the treatment for each group of mice to measure serum creatinine (Cr) and blood urea nitrogen (BUN). The blood was then centrifuged and separated to collect serum, and the urea nitrogen and creatinine contents in the serum were analyzed. Here, serum creatinine was measured using a mouse creatinine analysis kit (brand: Crystal Chem, model number: 80350), and serum urea nitrogen was measured using a urea analysis kit (brand: abcam, model number: ab83362). Mice from each group were sacrificed on day 7 (D7) after transplantation, and the left kidney of each mouse was perfused and formalin-fixed, then paraffin-embedded and tissue sections were cut out for H&E staining. The staining results were examined for morphological changes caused by ischemic injury based on histology, and the level of kidney damage was evaluated using Jablonski's semiquantitative standard, with 0 being normal tissue, 1 being tubular damage area less than 5%, 2 being tubular damage area 5% to 25%, 3 being tubular damage area 25% to 75%, and 4 being tubular damage area more than 75%.
[0047] The above results are shown in Table 1 below. From the results in Table 1, it can be seen that compared with the control group, the I / R group has a significant increase in the expression levels of urea nitrogen and creatinine in serum. This indicates that the renal injury model of the I / R group does indeed cause renal injury. Furthermore, the renal injury score results show that the I / R group has a score of 3 to 4 points, indicating that the renal tubule damage is severe. Meanwhile, compared with the I / R group, the mice in the group that received mitochondria had a significantly reduced content of urea nitrogen and creatinine in serum, indicating that mitochondria can effectively improve renal injury. In addition, the renal injury score results show that administration of mitochondria can restore damaged renal cells and improve the state of renal tubule injury, and the effect of improving renal injury also increases with the dose of mitochondria given.
[0048] Table 1: Analysis results of serum and kidney tissue sections after different treatments in each group of mice. JPEG2024133717000002.jpg86118
[0049] The above results indicate that when mitochondrial damage occurs in renal cells due to environmental factors such as fibrosis, oxidative stress, or inflammation, administering the mitochondrial extract provided by the present invention or a composition containing the same can effectively improve the mitochondrial damage in renal cells, thereby achieving the effect of improving or treating renal cell damage and related diseases.
Claims
[Claim 1] A composition for preventing and / or treating a kidney disorder-related disease, comprising mitochondria, A composition, wherein the amount of the mitochondria in the composition is 15 μg to 40 μg / 200 μL.
